id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC11533247
core_pubmed_pmc
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study Abstract Background: Crizanlizumab is a novel inhibitor of P-selectin, a key player in multicellular adhesion and inflammatory signaling, that leads to vaso...
PMC5620571
core_pubmed_pmc
Pharmacokinetic Analysis of an Oral Multicomponent Joint Dietary Supplement (Phycox ® ) in Dogs
Pharmacokinetic Analysis of an Oral Multicomponent Joint Dietary Supplement (Phycox ® ) in Dogs Abstract Despite the lack of safety, efficacy and pharmacokinetic (PK) studies, multicomponent dietary supplements (nutraceuticals) have become increasingly popular as primary or adjunct therapies for clinical osteoarthritis...
PMC4548431
core_pubmed_pmc
Predictive performance of Vancomycin population pharmacokinetic models in Iranian patients underwent hematopoietic stem cell transplantation
Predictive performance of Vancomycin population pharmacokinetic models in Iranian patients underwent hematopoietic stem cell transplantation Abstract Abstract Objective: Many hematopoietic stem cell transplantation (HSCT) patients receive vancomycin empirically during febrile neutropenia. There are several models for e...
PMC11405247
core_pubmed_pmc
A comprehensive review of artificial intelligence for pharmacology research
A comprehensive review of artificial intelligence for pharmacology research Abstract With the innovation and advancement of artificial intelligence, more and more artificial intelligence techniques are employed in drug research, biomedical frontier research, and clinical medicine practice, especially, in the field of p...
PMC4205704
core_pubmed_pmc
Modeling of Recovery Profiles in Mentally Disabled and Intact Patients after Sevoflurane Anesthesia; A Pharmacodynamic Analysis
Modeling of Recovery Profiles in Mentally Disabled and Intact Patients after Sevoflurane Anesthesia; A Pharmacodynamic Analysis Abstract Purpose Mentally disabled patients show different recovery profiles compared to normal patients after general anesthesia. However, the relationship of dose-recovery profiles of mental...
PMC12903145
core_pubmed_pmc
Big Data for Drug Discovery: Some Historical Landscape, Considerations, and Applications for a Medicinal Chemist
Big Data for Drug Discovery: Some Historical Landscape, Considerations, and Applications for a Medicinal Chemist Abstract Big Data (BD) has the potential to transform the process of drug discovery. The integration of chemical, biological, pharmacological, and clinical information facilitates the expeditious conception ...
PMC3084439
core_pubmed_pmc
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol Abstract Background. Lanthanum carbonate and sevelamer carbonate are non-calcium-based phosphate binders used to manage hyperphosphataemia in patients with chronic kidney disease (CKD). Patients with CKD may require int...
PMC10176964
core_pubmed_pmc
Predictive model of recurrent ischemic stroke: model development from real-world data
Predictive model of recurrent ischemic stroke: model development from real-world data Abstract Abstract Background There are established correlations between risk factors and ischemic stroke (IS) recurrence; however, does the hazard of recurrent IS change over time? What is the predicted baseline hazard of recurrent IS...
PMC11597875
core_pubmed_pmc
Comparative Pharmacokinetics and Egg Residues of Amoxicillin, Single and in Combination with Bromhexine, in Laying Hens
Comparative Pharmacokinetics and Egg Residues of Amoxicillin, Single and in Combination with Bromhexine, in Laying Hens Abstract Abstract The need for antibiotics in commercial laying hens is increasing owing to intensive farming systems. Amoxicillin trihydrate (AMX), an aminopenicillin β-lactam antibiotic, exerts broa...
PMC9099118
core_pubmed_pmc
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers Abstract Abstract Several inflammatory cytokines that promote inflammation and pathogenesis in asthma signal through the Janus kinase 1 (JAK1) pathway. This phase I, randomi...
PMC8876167
core_pubmed_pmc
A Transcriptomic Approach to Elucidate the Mechanisms of Gefitinib-Induced Toxicity in Healthy Human Intestinal Organoids
A Transcriptomic Approach to Elucidate the Mechanisms of Gefitinib-Induced Toxicity in Healthy Human Intestinal Organoids Abstract Abstract Gefitinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits the epidermal growth factor receptor (EGFR), hampering cell growth and proliferation. Due to its action, ge...
PMC7748388
core_pubmed_pmc
ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study
ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study Abstract Abstract Background Determining a suitable dose of intravenous colistimethate is challenging because of complicated pharmacokinetics, confus...
PMC9926069
core_pubmed_pmc
Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood and brain
Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood and brain Abstract Abstract Administration of a widely used 5‐hydroxytryptamine receptor (5HT 3A R) antagonist (ondansetron) potently inhibited the development of experimentally induced opioid dependence and withdrawal r...
PMC10353077
core_pubmed_pmc
Translating Kratom-Drug Interactions: From Bedside to Bench and Back
Translating Kratom-Drug Interactions: From Bedside to Bench and Back Abstract Abstract Kratom is a botanical natural product belonging to the coffee family, with stimulant effects at low doses and opioid-like effects at higher doses. During the last two decades, kratom has been purported as a safer alternative to pharm...
PMC10941510
core_pubmed_pmc
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients
In silico trial for the assessment of givinostat dose adjustment rules based on the management of key hematological parameters in polycythemia vera patients Abstract Abstract Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by excessive levels of platelets (PLT), white blood cells (WBC), an...
PMC12306784
core_pubmed_pmc
Tailoring oral targeted therapies dosage in lung cancer: A systematic review of pharmacokinetics studies on renal and hepatic impairment
Tailoring oral targeted therapies dosage in lung cancer: A systematic review of pharmacokinetics studies on renal and hepatic impairment Abstract Background Lung cancer is the leading cause of cancer-related deaths worldwide, and stage IV lung cancer is frequently managed with targeted therapy. Renal and hepatic impair...
PMC11613447
core_pubmed_pmc
Pharmacokinetic–Pharmacodynamic Modeling of the Immune-Enhancing Effect of Shikimic Acid in Growing Pigs
Pharmacokinetic–Pharmacodynamic Modeling of the Immune-Enhancing Effect of Shikimic Acid in Growing Pigs Abstract Abstract Shikimic acid (SA), extracted from the fruit of shikimi-no-ki, is used both as a preservative in the food industry and as an intermediate for a variety of active ingredients with a wide range of ph...
PMC7787627
core_pubmed_pmc
Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease
Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease Abstract Abstract Purpose No study has been evaluated pharmacokinetic (PK) and pharmacodynamic (PD) properties of β-lactam antibiotics in patients with acute kidney injury (AKI), not requiring ...
PMC6152655
core_pubmed_pmc
Determination and Pharmacokinetic Study of Three Diterpenes in Rat Plasma by UHPLC-ESI-MS/MS after Oral Administration of Rosmarinus officinalis L. Extract
Determination and Pharmacokinetic Study of Three Diterpenes in Rat Plasma by UHPLC-ESI-MS/MS after Oral Administration of Rosmarinus officinalis L. Extract Abstract Abstract Rosmarinus officinalis L. is commonly used as a spice and flavoring agent. Diterpenes are the main active compounds of R. officinalis . An Ultra H...
PMC8563277
core_pubmed_pmc
Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis
Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis Abstract Abstract Background Further work is required to understand the intrapulmonary pharmacokinetics of first-line anti-tuberculosis drugs. This study aimed to describe the plasma and intrapulmonary pharmacok...
PMC6883003
core_pubmed_pmc
Wedelolactone-Loaded Micelles Ameliorate Doxorubicin-Induced Oxidative Injury in Podocytes by Improving Permeability and Bioavailability
Wedelolactone-Loaded Micelles Ameliorate Doxorubicin-Induced Oxidative Injury in Podocytes by Improving Permeability and Bioavailability Abstract Wedelolactone (WED) is commonly used for the treatment of doxorubicin (DOX)-induced kidney damage, but its efficacy is limited by its poor solubility and bioavailability. In ...
PMC9155613
core_pubmed_pmc
Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis
Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis Abstract Abstract Background We evaluated Nix-TB trial data ( NCT02333799 , N = 109) to provide dosing recommendations to potentially minimize linezolid toxicity in patients with extensively drug-res...
PMC6354819
core_pubmed_pmc
Duration and onset of action of high dose U‐500 regular insulin in severely insulin resistant subjects with type 2 diabetes
Duration and onset of action of high dose U‐500 regular insulin in severely insulin resistant subjects with type 2 diabetes Abstract Abstract Aim Although regular human U‐500 insulin (U‐500) is frequently used for insulin resistant type 2 diabetics, pharmacokinetic and pharmacodynamic studies in these individuals are l...
PMC10008760
core_pubmed_pmc
Multivariate analysis of PET pharmacokinetic parameters improves inferential efficiency
Multivariate analysis of PET pharmacokinetic parameters improves inferential efficiency Abstract Abstract Purpose In positron emission tomography quantification, multiple pharmacokinetic parameters are typically estimated from each time activity curve. Conventionally all but the parameter of interest are discarded befo...
PMC8007809
core_pubmed_pmc
Developing a medium combination to attain similar glycosylation profile to originator by DoE and cluster analysis method
Developing a medium combination to attain similar glycosylation profile to originator by DoE and cluster analysis method Abstract Glycosylation is critical for monoclonal antibody production because of its impact on pharmacokinetics and pharmacodynamics. Modulation of glycan profile is frequently needed in biosimilar d...
PMC7498943
core_pubmed_pmc
Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract
Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract Abstract Cannabidiol (CBD)-rich hemp extract use is increasing in veterinary medicine with little examination of serum cann...
PMC10311652
core_pubmed_pmc
Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects
Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects Abstract Abstract Molecularly targeted radionuclide therapies (TRTs) struggle with balancing efficacy and safety, as current strategies to increase tumor absorption often alter drug pharmacokinetics to prolong circulation and normal tissue i...
PMC11582109
core_pubmed_pmc
Population Pharmacokinetics of Vancomycin in Intensive Care Patients with the Time-Varying Status of Temporary Mechanical Circulatory Support or Continuous Renal Replacement Therapy
Population Pharmacokinetics of Vancomycin in Intensive Care Patients with the Time-Varying Status of Temporary Mechanical Circulatory Support or Continuous Renal Replacement Therapy Abstract Abstract Introduction This study characterized the population pharmacokinetics (PK) of vancomycin in patients treated with and wi...
PMC7022228
core_pubmed_pmc
Extended Intake of Mulberry Leaf Extract Delayed Metformin Elimination via Inhibiting the Organic Cation Transporter 2
Extended Intake of Mulberry Leaf Extract Delayed Metformin Elimination via Inhibiting the Organic Cation Transporter 2 Abstract Abstract Diabetes mellitus (DM) has become a major health problem in most countries of the world. DM causes many complications, including hyperglycemia, diabetic ketoacidosis, and death. In As...
PMC6370782
core_pubmed_pmc
Synthesis of [ 18 F]Favipiravir and Biodistribution in C3H/HeN Mice as Assessed by Positron Emission Tomography
Synthesis of [ 18 F]Favipiravir and Biodistribution in C3H/HeN Mice as Assessed by Positron Emission Tomography Abstract Favipiravir (T705; 6-fluoro-3-hydroxypyrazine-2-carboxamide) is a pyrazine analog that has demonstrated potent antiviral activity against a broad spectrum of viruses in multiple in vivo disease model...
PMC11901399
core_pubmed_pmc
Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe
Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe Abstract ABSTRACT Aims To demonstrate pharmacokinetic equivalence of CT‑P39 administered via auto-injector (CT‑P39 AI) and European Union–approved reference omalizumab via pre-filled syringe (EU-OMA PFS...
PMC6153839
core_pubmed_pmc
Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam
Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam Abstract The combination product meropenem-vaborbactam, with activity against KPC-producing carbapenem-resistant Enterobacteriaceae , is likely to be used during renal replacement th...
PMC5944028
core_pubmed_pmc
Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711
Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711 Abstract Background Cathepsin K is an attractive therapeutic target for diseases in which bone resorption is excessive such as osteoporosis and osteoarthritis (OA). The current paper characterized the pha...
PMC7482493
core_pubmed_pmc
CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity
CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity Abstract Abstract Background Regulatory T cells (T regs ) contribute to an immunosuppressive tumor microenvironment. They play an important role in the establishment and progression of tu...
PMC6588584
core_pubmed_pmc
RETRACTED ARTICLE: Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle
RETRACTED ARTICLE: Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle Abstract The anti-angiogenic agent, diamino propane tetraiodothyroacetic acid (DAT), is a thyro-integrin (integrin αvβ3) antagonist anticancer...
PMC6664420
core_pubmed_pmc
Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteers
Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteers Abstract Background and objective IDP-73152 mesylate is a peptide deformylase inhibitor under investigation for the treatment of complicated skin and respiratory tract infecti...
PMC12643817
core_pubmed_pmc
Impact of Dihydrocapsaicin on the Metabolism of Efavirenz In Vitro and In Vivo
Impact of Dihydrocapsaicin on the Metabolism of Efavirenz In Vitro and In Vivo Abstract ABSTRACT Efavirenz (EFV) is the first‐line treatment for acquired immunodeficiency syndrome. However, capsaicin may affect its properties, although the underlying mechanisms remain unknown. This study aimed to investigate the effect...
PMC9506137
core_pubmed_pmc
Advanced Drug Delivery Micro- and Nanosystems for Cardiovascular Diseases
Advanced Drug Delivery Micro- and Nanosystems for Cardiovascular Diseases Abstract Advanced drug delivery micro- and nanosystems have been widely explored due to their appealing specificity/selectivity, biodegradability, biocompatibility, and low toxicity. They can be applied for the targeted delivery of pharmaceutical...
PMC4592533
core_pubmed_pmc
Cloud Computing for Pharmacometrics: Using AWS, NONMEM, PsN, Grid Engine, and Sonic
Cloud Computing for Pharmacometrics: Using AWS, NONMEM, PsN, Grid Engine, and Sonic Abstract Abstract Cloud computing allows pharmacometricians to access advanced hardware, network, and security resources available to expedite analysis and reporting. Cloud-based computing environments are available at a fraction of the...
PMC10669389
core_pubmed_pmc
Prospection of Peptide Inhibitors of Thrombin from Diverse Origins Using a Machine Learning Pipeline
Prospection of Peptide Inhibitors of Thrombin from Diverse Origins Using a Machine Learning Pipeline Abstract Thrombin is a key enzyme involved in the development and progression of many cardiovascular diseases. Direct thrombin inhibitors (DTIs), with their minimum off-target effects and immediacy of action, have great...
PMC10034346
core_pubmed_pmc
Investigation of inner ear drug delivery with a cochlear catheter in piglets as a representative model for human cochlear pharmacokinetics
Investigation of inner ear drug delivery with a cochlear catheter in piglets as a representative model for human cochlear pharmacokinetics Abstract Abstract Hearing impairment is the most common sensory disorder in humans, and yet hardly any medications are licensed for the treatment of inner ear pathologies. Intricate...
PMC11398290
core_pubmed_pmc
EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
EFFICACY AND SAFETY OF THE PROPOSED BIOSIMILAR AFLIBERCEPT, SDZ-AFL, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Abstract Supplemental Digital Content is Available in the Text. The Phase 3 Mylight study confirmed that proposed biosimilar aflibercept (SOK583A1; Sandoz) is clinically equivalent to its r...
PMC9535356
core_pubmed_pmc
Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma Abstract Abstract Introduction The combination of lenvatinib plus pembrolizumab demonstrated a relevant clinical benefit in patients with endometrial carcinoma. The safety profile was consistent with the e...
PMC9662862
core_pubmed_pmc
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS G12C -Mutant Non–Small Cell Lung Cancer
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS G12C -Mutant Non–Small Cell Lung Cancer Abstract Abstract Purpose: Patients with KRAS-mutant non–small cell lung cancer (NSCLC) with brain metastases (BM) have a poor prognosis. Adagrasib (MRTX849), a poten...
PMC6749572
core_pubmed_pmc
Development of 11-DGA-3- O -Gal-Modified Cantharidin Liposomes for Treatment of Hepatocellular Carcinoma
Development of 11-DGA-3- O -Gal-Modified Cantharidin Liposomes for Treatment of Hepatocellular Carcinoma Abstract Background: Liver cancer is a common malignant tumor worldwide, and its morbidity and mortality increase each year. The disease has a short course and high mortality, making it a serious threat to human hea...
PMC11471682
core_pubmed_pmc
An insight into pharmacokinetics and dose optimization of antimicrobials agents in elderly patients
An insight into pharmacokinetics and dose optimization of antimicrobials agents in elderly patients Abstract The global elderly population is on the rise, and infections tend to have a higher mortality rate among older individuals. Aging is associated with the progressive impairment of multi-organ function, which can i...
PMC6133033
core_pubmed_pmc
Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015
Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015 Abstract Abstract Coagulase-negative staphylococci (CoNS) are a significant cause of bacteraemia, the treatment of which is becoming increasingly complex due to the emergence of mult...
PMC5027041
core_pubmed_pmc
Herb-Drug Interaction: Effects of Relinqing® Granule on the Pharmacokinetics of Ciprofloxacin, Sulfamethoxazole, and Trimethoprim in Rats
Herb-Drug Interaction: Effects of Relinqing® Granule on the Pharmacokinetics of Ciprofloxacin, Sulfamethoxazole, and Trimethoprim in Rats Abstract Abstract Relinqing granule (RLQ) is the best-selling Chinese patent drug for treatment of urinary system diseases. In this study, the effects of RLQ on the pharmacokinetics ...
PMC5425492
core_pubmed_pmc
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus Abstract Background Absorption of current rapid-acting insulins is too slow for patients with diabetes mellitus to achieve optimal postpr...
PMC5534524
core_pubmed_pmc
Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients
Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients Abstract Type 2 diabetes mellitus is a worldwide epidemic disorder with considerable health and economic consequences. Metformin is one of the most commonly prescribed oral antidiabetic drugs. Pharmacogenetic studies showed that...
PMC10276593
core_pubmed_pmc
Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3
Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3 Abstract Background Recombinant von Willebrand factor (rVWF, vonicog alfa, Vonvendi/Veyvondi, Takeda Pharmaceuticals USA, Lexington, MA) and several plasma-derived VWF/factor...
PMC3592804
core_pubmed_pmc
Bayesian Inference for Generalized Linear Mixed Model Based on the Multivariate t Distribution in Population Pharmacokinetic Study
Bayesian Inference for Generalized Linear Mixed Model Based on the Multivariate t Distribution in Population Pharmacokinetic Study Abstract Abstract This article provides a fully Bayesian approach for modeling of single-dose and complete pharmacokinetic data in a population pharmacokinetic (PK) model. To overcome the i...
PMC8191022
core_pubmed_pmc
Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling
Pharmacokinetics and pharmacodynamics of enrofloxacin treatment of Escherichia coli in a murine thigh infection modeling Abstract Abstract Background Enrofloxacin is an antibacterial drug with broad-spectrum activity that is widely indicated for veterinary use. We aim to develop the clinical applications of Enrofloxaci...
PMC12075530
core_pubmed_pmc
Antidepressant-like activity of Bezafibrate in mice models of depression: a behavioral and neurobiological characterization
Antidepressant-like activity of Bezafibrate in mice models of depression: a behavioral and neurobiological characterization Abstract Background Depression represents a major global public health challenge, inflicting profound suffering on patients while imposing substantial socioeconomic burdens on families and healthc...
PMC9867071
core_pubmed_pmc
Pharmacodynamics, Pharmacokinetics, and Kidney Distribution of Raw and Wine-Steamed Ligustri Lucidi Fructus Extracts in Diabetic Nephropathy Rats
Pharmacodynamics, Pharmacokinetics, and Kidney Distribution of Raw and Wine-Steamed Ligustri Lucidi Fructus Extracts in Diabetic Nephropathy Rats Abstract The purpose of this study was to investigate differences in the pharmacodynamic, pharmacokinetic, and kidney distribution between Ligustri Lucidi Fructus (LLF) and w...
PMC12104396
core_pubmed_pmc
Comparative in vitro assessment of CYP2C19 inhibition by ilaprazole and conventional proton pump inhibitors using a high throughput fluorometric assay
Comparative in vitro assessment of CYP2C19 inhibition by ilaprazole and conventional proton pump inhibitors using a high throughput fluorometric assay Abstract Abstract Proton pump inhibitors (PPIs) are commonly used anti-ulcer agents, known to inhibit CYP2C19, leading to pharmacokinetic drug-drug interactions (DDIs). ...
PMC4452040
core_pubmed_pmc
Pharmacokinetics and biodistribution of negatively charged pectin nanoparticles encapsulating paclitaxel
Pharmacokinetics and biodistribution of negatively charged pectin nanoparticles encapsulating paclitaxel Abstract Abstract Pectin, a naturally occurring biopolymer has been found to have increasing applications in the pharmaceutical and biotechnology industry. Sugars with their three-dimensional structures are importan...
PMC4296750
core_pubmed_pmc
Quantitative PCR Analysis of DNA Aptamer Pharmacokinetics in Mice
Quantitative PCR Analysis of DNA Aptamer Pharmacokinetics in Mice Abstract Abstract DNA aptamer oligonucleotides and their protein conjugates show promise as therapeutics in animal models of diseases such as multiple sclerosis. These molecules are large and highly charged, raising questions about their biodistribution ...
PMC9643842
core_pubmed_pmc
The role of nanomaterials in enhancing natural product translational potential and modulating endoplasmic reticulum stress in the treatment of ovarian cancer
The role of nanomaterials in enhancing natural product translational potential and modulating endoplasmic reticulum stress in the treatment of ovarian cancer Abstract Abstract Ovarian cancer, and particularly its most frequent type, epithelial ovarian carcinoma, constitutes one of the most dangerous malignant tumors am...
PMC5651339
core_pubmed_pmc
Evidence-based review of statin use in patients with HIV on antiretroviral therapy
Evidence-based review of statin use in patients with HIV on antiretroviral therapy Abstract Highlights • Cardiovascular disease is up to two times more prevalent in patient with HIV. • Based on pharmacokinetic and clinical data, atorvastatin and pravastatin are generally considered safe for HIV patients receiving ART. ...
PMC12255638
core_pubmed_pmc
Pharmacokinetics of Atogepant in Healthy Lactating Female Participants: Results from a Phase 1 Lactation Study
Pharmacokinetics of Atogepant in Healthy Lactating Female Participants: Results from a Phase 1 Lactation Study Abstract Abstract Introduction Atogepant is approved for the preventive treatment of migraine and is taken orally once daily. This work aimed to characterize the plasma and milk pharmacokinetics of atogepant i...
PMC11401510
core_pubmed_pmc
Effect of body size on the oral pharmacokinetics of oxytetracycline in rainbow trout ( Oncorhynchus mykiss )
Effect of body size on the oral pharmacokinetics of oxytetracycline in rainbow trout ( Oncorhynchus mykiss ) Abstract Objective The aim of this study was to determine the plasma pharmacokinetics of oxytetracycline (OTC) in rainbow trout ( Oncorhynchus mykiss ) of different body sizes. Methods The research was carried o...
PMC7148456
core_pubmed_pmc
Successful High-Dosage Monotherapy of Tigecycline in a Multidrug-Resistant Klebsiella pneumoniae Pneumonia–Septicemia Model in Rats
Successful High-Dosage Monotherapy of Tigecycline in a Multidrug-Resistant Klebsiella pneumoniae Pneumonia–Septicemia Model in Rats Abstract Abstract Background: Recent scientific reports on the use of high dose tigecycline monotherapy as a “drug of last resort” warrant further research into the use of this regimen for...
PMC9456159
core_pubmed_pmc
Synthesis and Biological Evaluation of Thiazole-Based Derivatives with Potential against Breast Cancer and Antimicrobial Agents
Synthesis and Biological Evaluation of Thiazole-Based Derivatives with Potential against Breast Cancer and Antimicrobial Agents Abstract Investigating novel, biologically-active coordination compounds that may be useful in the design of breast anticancer, antifungal, and antimicrobial agents is still the main challenge...
PMC8405503
core_pubmed_pmc
Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center study
Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center study Abstract Abstract Modeling of retrospectively collected multi-center data of a rare disease in pediatrics is challenging because laboratory data can stem from several decad...
PMC5093100
core_pubmed_pmc
Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock
Impact of a high loading dose of amikacin in patients with severe sepsis or septic shock Abstract Background The therapeutic effect of aminoglycosides is highest and optimal when the peak plasma concentration ( C max )/minimal inhibitory concentration (MIC) ratio is between 8 and 10. The French guidelines recommend to ...
PMC9617675
core_pubmed_pmc
In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2
In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2 Abstract Abstract FB2001 is a drug candidate that targets the main protease of SARS-CoV-2 via covalently binding to cysteine 145. In this study, we evaluated the inhibitory activities of FB2001 against several SARS-CoV-2 variants i...
PMC4197178
core_pubmed_pmc
Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation
Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation Abstract Abstract Background/Aims The dose of mycophenolate mofetil (MMF) has been reduced in Asia due to side effects associated with the conventional fixed dose of 2-3 g/day. We aimed to determine the pharma...
PMC9227314
core_pubmed_pmc
Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs
Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs Abstract Cancer is the second most common cause of death in the United States, accounting for 602,350 deaths in 2020. Cancer-related death rates have declined by 27% over the past two decades, partially due to the identific...
PMC9641194
core_pubmed_pmc
Assessment of potential drug–drug interactions among outpatients in a tertiary care hospital: focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study)
Assessment of potential drug–drug interactions among outpatients in a tertiary care hospital: focusing on the role of P-glycoprotein and CYP3A4 (retrospective observational study) Abstract Abstract Background Selecting a medicine has a significant impact on the quality of therapy including efficacy and safety. P-glycop...
PMC10237419
core_pubmed_pmc
Habitual exercise evokes fast and persistent adaptation during split-belt walking
Habitual exercise evokes fast and persistent adaptation during split-belt walking Abstract Abstract Changing movement patterns in response to environmental perturbations is a critical aspect of gait and is related to reducing the energetic cost of the movement. Exercise improves energetic capacity for submaximal exerci...
PMC9926082
core_pubmed_pmc
EDP ‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects
EDP ‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects Abstract Abstract EDP‐297 is a farnesoid X receptor agonist under development for treating nonalcoholic steatohepatitis. The pharmacokinetic (PK), pharmacodynamic (PD), food effect, and safety were evaluated in a single ascen...
PMC9346281
core_pubmed_pmc
Remimazolam – current knowledge on a new intravenous benzodiazepine anesthetic agent
Remimazolam – current knowledge on a new intravenous benzodiazepine anesthetic agent Abstract Intravenous anesthetic agents such as midazolam, propofol, and ketamine are routinely used to provide anesthesia and sedation. They have been shown to effectively induce and maintain amnesia, sedation, and hypnosis in various ...
PMC4590727
core_pubmed_pmc
Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intranasal route
Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intranasal route Abstract Abstract Intranasal drug administration is receiving increased attention as a delivery method for bypassing the blood–brain barrier and rapidly targeting therapeutics to the CNS. However, rapid mucocil...
PMC6008299
core_pubmed_pmc
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials Abstract Abstract Background We examined the impact of race on the maximum tolerated doses (MTD) and final approved doses (FAD) of single-agent molecular-targeted agents (MTA) in North America/Europe (NA/EU) and Asia. Methods W...
PMC9229780
core_pubmed_pmc
Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach
Nobiletin as a Neuroprotectant against NMDA Receptors: An In Silico Approach Abstract Abstract Excitotoxicity is a type of neurodegenerative disorder. It caused by excessive glutamate receptor activation, which leads to neuronal malfunction and fatality. The N-methyl-D-aspartate (NMDA) receptors are found in glutamater...
PMC11979114
core_pubmed_pmc
Innovative applications and future perspectives of chromatography-mass spectrometry in drug research
Innovative applications and future perspectives of chromatography-mass spectrometry in drug research Abstract Abstract Chromatography coupled with mass spectrometry (MS) has emerged as a cornerstone analytical technique in drug research. Over the years, advancements in chromatography-MS have significantly enhanced its ...
PMC11619384
core_pubmed_pmc
Development of a new Acinetobacter baumannii pneumonia rabbit model for the preclinical evaluation of future anti-infective strategies
Development of a new Acinetobacter baumannii pneumonia rabbit model for the preclinical evaluation of future anti-infective strategies Abstract ABSTRACT Carbapenem-resistant Acinetobacter baumannii (CRAB) is an emerging cause of hospital-acquired pneumonia (HAP). Preclinical large models are warranted to predict the ef...
PMC7449315
core_pubmed_pmc
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors Abstract Background M4112 is an oral, potent, and selective indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-d...
PMC8070888
core_pubmed_pmc
Intravenous Vipera berus Venom-Specific Fab Fragments and Intramuscular Vipera ammodytes Venom-Specific F(ab’) 2 Fragments in Vipera ammodytes -Envenomed Patients
Intravenous Vipera berus Venom-Specific Fab Fragments and Intramuscular Vipera ammodytes Venom-Specific F(ab’) 2 Fragments in Vipera ammodytes -Envenomed Patients Abstract Vipera ammodytes ( V. ammodytes ) is the most venomous European viper. The aim of this study was to compare the clinical efficacy and pharmacokineti...
PMC12567268
core_pubmed_pmc
The Effects of Ritonavir on the Pharmacokinetics of Tofacitinib in Rats
The Effects of Ritonavir on the Pharmacokinetics of Tofacitinib in Rats Abstract Background and Objective : Tofacitinib (TOF), an oral Janus kinase inhibitor used to treat rheumatoid arthritis (RA), is extensively metabolized by cytochrome P450 (CYP) 3A4. Ritonavir (RTV), a protease inhibitor, is commonly used as a pha...
PMC9309697
core_pubmed_pmc
S -Ketamine Oral Thin Film—Part 1: Population Pharmacokinetics of S -Ketamine, S -Norketamine and S -Hydroxynorketamine
S -Ketamine Oral Thin Film—Part 1: Population Pharmacokinetics of S -Ketamine, S -Norketamine and S -Hydroxynorketamine Abstract Ketamine is administered predominantly via the intravenous route for the various indications, including anesthesia, pain relief and treatment of depression. Here we report on the pharmacokine...
PMC6692352
core_pubmed_pmc
DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain
DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain Abstract Abstract Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of several anti-neoplastics and a main cause of sensory disturbances in cancer survivors, negatively impacting p...
PMC9790683
core_pubmed_pmc
Quantitative in vitro to in vivo extrapolation for developmental toxicity potency of valproic acid analogues
Quantitative in vitro to in vivo extrapolation for developmental toxicity potency of valproic acid analogues Abstract Abstract Background The developmental toxicity potential (dTP) concentration from the devTOX quick Predict (devTOX qP ) assay, a metabolomics‐based human induced pluripotent stem cell assay, predicts a ...
PMC9287213
core_pubmed_pmc
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide Abstract Abstract Background and Objective Tirzepatide, a novel, once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, is approved in the US as a treatment ...
PMC7886780
core_pubmed_pmc
Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia
Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia Abstract Background Acute lymphoblastic leukemia (ALL) is the most common hematologic malignancy in children. It requires a long and rigorous course of chemother...
PMC10091977
core_pubmed_pmc
Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study
Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open‐Label, Single‐Dose, Parallel Group Study Abstract Abstract Maribavir, an orally bioavailable antiviral, has shown superior activity against posttransplant cytomegalovirus infection compared with conventional antivira...
PMC7004511
core_pubmed_pmc
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer Abstract Abstract Patients with epidermal growth factor receptor ( EGFR )‐mutated non‐small cell lung cancer (NSCLC) harboring BIM deletion polymorphism ( BIM deletion) have poor...
PMC10864936
core_pubmed_pmc
Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV
Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV Abstract Abstract Pharmacokinetic (PK) studies in children are usually small and have ethical constraints due to the medical complexities of drawing blood in this special po...
PMC11694536
core_pubmed_pmc
Discovery and clinical translation of ceperognastat, an O‐GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease
Discovery and clinical translation of ceperognastat, an O‐GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's disease Abstract Abstract INTRODUCTION The aggregation and spread of hyperphosphorylated, pathological tau in the human brain is hypothesized to play a key role in Alzheimer's disease (AD) as well as ot...
PMC11098158
core_pubmed_pmc
Deep‐NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data
Deep‐NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data Abstract Abstract Noncompartmental analysis (NCA) is a model‐independent approach for assessing pharmacokinetics (PKs). Although the existing NCA algorithms are very well‐established and widely utilized, they suffer f...
PMC4464227
core_pubmed_pmc
A multi-center, open-label trial to compare the efficacy and pharmacokinetics of Artemether-Lumefantrine in children with severe acute malnutrition versus children without severe acute malnutrition: study protocol for the MAL-NUT study
A multi-center, open-label trial to compare the efficacy and pharmacokinetics of Artemether-Lumefantrine in children with severe acute malnutrition versus children without severe acute malnutrition: study protocol for the MAL-NUT study Abstract Abstract Background Malnutrition and malaria frequently coexist in sub-Saha...
PMC5835461
core_pubmed_pmc
Fast‐acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose‐lowering effect relative to insulin aspart
Fast‐acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose‐lowering effect relative to insulin aspart Abstract Abstract Introduction Fast‐acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with two added excipients...
PMC8355837
core_pubmed_pmc
A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients
A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients Abstract Abstract BLZ-100 (tozuleristide) is an intraoperative fluorescent imaging agent that selectively detects malignant tissue and can be used in real time to guide tumor resection. The purpose of this stu...
PMC10537177
core_pubmed_pmc
Stability Study of Fosfomycin in Elastomeric Pumps at 4 °C and 34 °C: Technical Bases for a Continuous Infusion Use for Outpatient Parenteral Antibiotic Therapy
Stability Study of Fosfomycin in Elastomeric Pumps at 4 °C and 34 °C: Technical Bases for a Continuous Infusion Use for Outpatient Parenteral Antibiotic Therapy Abstract Background: Fosfomycin acts against aerobic Gram−/+ bacteria by blocking the synthesis of peptidoglycan. Its use has been currently re-evaluated for i...
PMC9788528
core_pubmed_pmc
New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate
New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate Abstract Abstract (1) Background: In their 60-year history, dimethyl fumarate and other salts of fumaric acid have been used for the treatment of psoriasis and other immune-mediated diseases for ...
PMC11667501
core_pubmed_pmc
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology
Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology Abstract Abstract INTRODUCTION Semorinemab, an anti‐tau monoclonal antibody, was assessed in two Phase II trials for Alzheimer's disease (AD). Plasma and cerebrospinal fluid (CSF) biomarkers provided insights into...
PMC5838028
core_pubmed_pmc
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma Abstract Abstract Background I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codritu...
PMC6027276
core_pubmed_pmc
Review of Intraocular Pharmacokinetics of Anti-Infectives Commonly Used in the Treatment of Infectious Endophthalmitis
Review of Intraocular Pharmacokinetics of Anti-Infectives Commonly Used in the Treatment of Infectious Endophthalmitis Abstract Abstract Although intravitreal administration of anti-infectives represents the standard treatment for infectious endophthalmitis, the knowledge about their pharmacokinetics is still limited. ...
PMC4133055
core_pubmed_pmc
The synthetic glucocorticoids prednisolone and dexamethasone regulate the same genes in acute lymphoblastic leukemia cells
The synthetic glucocorticoids prednisolone and dexamethasone regulate the same genes in acute lymphoblastic leukemia cells Abstract Background Glucocorticoids (GCs) cause apoptosis in malignant cells of lymphoid lineage by transcriptionally regulating a plethora of genes. As a result, GCs are included in almost all tre...